BY USING THIS SITE YOU ACKNOWLEDGE THAT GENENTECH, INC. AND NOVARTIS PHARMACEUTICALS CORPORATION ARE PROVIDING THE MATERIAL FOR INFORMATIONAL PURPOSES ONLY AND THAT NEITHER GENENTECH, INC., NOR NOVARTIS PHARMACEUTICALS CORPORATION, NOR THEIR AGENTS, AFFILIATES, PARTNERS, OR LICENSORS ARE PROVIDING THE MATERIALS TO YOU FOR THE PURPOSES OF GIVING YOU MEDICAL ADVICE. YOU SHOULD NOT RELY ON THE MATERIALS IN DECIDING ON A TREATMENT PLAN, DRUG USAGE, OR ANY OTHER MEDICAL ADVICE REGARDING THE MATERIALS, AND GENENTECH, INC., NOVARTIS PHARMACEUTICALS CORPORATION, AND THEIR LICENSORS STRONGLY URGE THAT YOU CONSULT WITH A PHYSICIAN IN CONNECTION WITH ANY AND ALL TREATMENT OPTIONS THAT MAY BE AVAILABLE TO YOU.

BY USING THIS WEBSITE, YOU ACCEPT THE INFORMATION, PRODUCTS, AND SERVICES PROVIDED HEREIN "AS IS." GENENTECH, INC. AND NOVARTIS PHARMACEUTICALS CORPORATION MAKE NO EXPRESS OR IMPLIED WARRANTY REGARDING THE ACCURACY, CONTENT, COMPLETENESS, RELIABILITY, OPERABILITY, OR LEGALITY OF INFORMATION CONTAINED WITHIN THIS WEB SITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF PROPRIETARY RIGHTS. IN NO EVENT SHALL GENENTECH, INC., NOVARTIS PHARMACEUTICALS CORPORATION, OR ITS AGENTS, AFFILIATES, PARTNERS, OR LICENSORS BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS RELATED TO THE USE OF OUR WEB SITES, WHETHER IN AN ACTION OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, OR OTHER TORTIOUS ACTION ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE MATERIALS CONTAINED ON THIS SITE.

	WHO is XOLAIR for?
	XOLAIR® (omalizumab) for subcutaneous use is an injectable, prescription medicine for patients ages 12 and older. It is for patients with moderate to severe persistent allergic asthma caused by year-round allergens in the air. A skin or blood test is done to see if you have allergic asthma. XOLAIR is for patients who are not controlled by asthma medicines called inhaled steroids.
	XOLAIR helps reduce the number of asthma attacks in people with allergic asthma who still have asthma symptoms even though they are taking inhaled steroids.
	Important Limitations of Use
	XOLAIR has not been proven to work in other allergic conditions. XOLAIR is not a rescue medicine and should not be used to treat sudden asthma attacks. XOLAIR should not be used in children under 12 years of age.
	IMPORTANT SAFETY INFORMATION
	XOLAIR should always be injected in a doctor's office. You should read the Medication Guide before starting XOLAIR treatment and before each and every treatment.
	A severe allergic reaction called anaphylaxis has happened in some patients after they received XOLAIR. Anaphylaxis is a life-threatening condition and can lead to death. Seek emergency medical treatment right away if symptoms occur. Signs and symptoms of anaphylaxis include:
	wheezing, shortness of breath, cough, chest tightness, or trouble breathing low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom" flushing, itching, hives, or feeling warm swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing
	You should not receive XOLAIR if you have ever had an allergic reaction to a XOLAIR injection. Do not use XOLAIR if you are allergic to any of its ingredients.
	In clinical studies 0.5% of patients receiving XOLAIR developed cancer, compared to 0.2% of patients receiving placebo (an injection with no active medicine).
	Joint inflammation or pain, rash, fever, and swollen lymph nodes have been seen in patients taking XOLAIR. Talk to your doctor if you’ve experienced any of these signs and symptoms.
	In patients >12 years of age, the most commonly observed side effects in asthma studies that had a >1% difference between XOLAIR and placebo were joint pain (8%), pain (general) ( 7%), leg pain (4%), tiredness (fatigue) (3%), dizziness (3%), fracture (2%), arm pain (2%), itching (2%), inflammation of the skin (2%), and earache (2%).
	In asthma studies, the most common side effects in patients, who either needed to stop XOLAIR or needed medical attention, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and sore throat (11%). These side effects were seen at the same rates in XOLAIR-treated patients as in patients in the control group who received placebo.
	XOLAIR is not a rescue medicine and should not be used to treat sudden asthma attacks.
	XOLAIR is not a substitute for the medicines you are already taking. Do not change or stop taking any of your other asthma medicines unless your doctor tells you to do so. You may not see an immediate improvement in your asthma when beginning XOLAIR therapy.
	You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by calling 1-800-FDA-1088. You may also report any side effects at 1-866-4XOLAIR (1-866-496-5247).
	Talk to your doctor for more information and if you have any questions about your treatment.
	Please see full Prescribing Information and Medication Guide for additional important safety information.